Tartrate-resistant acid phosphatase isoform 5a as an inflammation marker in end-stage renal disease

Clinical Nephrology

Volumn 71, Issue 4, 2009, Pages 387-396

  Janckila, Anthony J ^a,b   Lederer, E D ^b   Price, B A ^b   Yam, L T ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b University of Louisville School of Medicine   (United States)

Author keywords

Bone resorption; Chronic kidney disease; Immunoassay; Inflammation; Tartrate resistant acid phosphatase

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ALBUMIN; ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; C REACTIVE PROTEIN; CHOLESTEROL; FERRITIN; FETUIN A; HEMOGLOBIN; INTERLEUKIN 6; PARATHYROID HORMONE; PHOSPHATASE; TARTRATE RESISTANT ACID PHOSPHATASE ISOFORM 5A; TARTRATE RESISTANT ACID PHOSPHATASE ISOFORM 5B; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BONE DENSITY; CHRONIC INFLAMMATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME IMMUNOASSAY; FEMALE; FERRITIN BLOOD LEVEL; GOLD STANDARD; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; NUTRITIONAL STATUS; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 66649136462     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CNP71387     Document Type: Article

References (42)

1. Alatalo SL, Ivaska KK, Wagnespack SG, Econs MJ, Väänänen HK, Halleen JM. Osteoclast-derived tartrate-resistant acid phosphatase 5b in Albers-Schoenberg disease (Type II autosomal-dominant osteopetrosis). Clin Chem. 2004; 50: 883-890.
2. Angel NZ, Walsh N, Forwood MR, Ostrowski MC, Cassady AI, Hume DA. Transgenic mice overexpressing tartrate-resistant acid phosphatase exhibit an increased rate of bone turnover. J Bone Miner Res. 2000; 15: 103-110.
3. Bervoets ARJ, Spasovski GB, Behets GJ, Dams G, Polenakovic MH, Zafirovska K, Van Hoof VO, De Broe ME, D'Haese PC. Useful biochemical markers for diagnosing renal osteodystrophy in predialysis end-stage renal failure patients. Am J Kidney Dis. 2003; 41: 997-1007.
4. Chao T-Y, Lee S-H, Chen MM, Neustadt DH, Chaudhry UA, Yam LT, Janckila AJ. Development of immunoassays for serum tartrate-resistant acid phosphatase isoform 5a. Clin Chim Acta. 2005; 359: 132-140.
5. Chu P, Chao T-Y, Lin Y-F, Janckila AJ, Yam LT. Correlation between histomorphometric parameters of bone resorption and serum Type 5b tartrate-resistant acid phosphatase in uremic patients on maintenance hemodialysis. Am J Kidney Dis. 2003; 41: 1052-1059.
6. Cottone S et al. Association between biomarkers of inflammation and left ventricular hypertrophy in moderate chronic kidney disease. Clin Nephrol 2007; 67: 209-216.
7. Esfandiari E, Bailey M, Stokes CR, Cox TM, Evans MJ, Hayman AR. TRACP influences Th1 pathways by affecting dendritic cell function. J Bone Miner Res. 2006; 21: 1367-1376.
8. Fruchart J-C, Nierman MC, Stroes ESG, Kastelein JJP, Duriez P. Newrisk factors for atherosclerosis and patient risk assessment. Circulation. 2004; 109 (23 Suppl. 1): III15-III19.
9. Gerdhem P, Ivaska KK, Alatalo SL, Halleen JM, Hellman J, Osaksson A, Pettersson K, Väänänen HK, Akesson K, Obrant KJ. Biochemical markers of bone metabolism and prediction of fracture in elderly women. J Bone Miner Res. 2004; 19: 386-393.
10. Haffner SM. Abdominal adiposity and cardiometabolic risk: Do we have all the answers? Am J Med. 2007; 120 (Suppl. A): S10-S17.
11. Halleen JM, Ylipahkala H, Alatalo SL, Janckila AJ, Hiekkinen JE, Suominen H, Cheng S, Väänänen HK. Serumtartrate-resistant acid phosphatase 5b, but not 5a, correlates with other markers of bone turnover and bone mineral density. Calcif Tissue Int. 2002; 71: 20-25.
12. Hayman AR, Jones SJ, Boyde A, Foster D, Colledge WH, Carlton MB, Evans MJ, Cox TM. Mice lacking tartrate-resistant acid phosphatase (Acp5) have disrupted endochondral ossification and mild osteopetrosis. Development. 1996; 122: 3151-3162.
13. Honda H, Qureshi AR, Heimbürger O, Barany P, Wang K, Pecoits-Filho R, Stenvinkel P, Lindholm B. Serum albumin, C-reactive protein, interleukin-6, and fetuin A as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD. Am J Kidney Dis. 2006; 47: 139-148.
14. Ikizler TA, Wingard RL, Harvell J, Shyr Y, Hakim RM. Association of morbidity with markers of nutrition and inflammation in chronic hemodialysis patients: A prospective study. Kidney Int. 1999; 55: 1945-1951.
15. Janckila AJ, Takahashi K, Sun SZ, Yam LT. Tartrate-resistant acid phosphatase isoform 5b as serum marker for osteoclastic activity. Clin Chem. 2001; 47: 74-80.
16. Janckila AJ, Neustadt DH, Nakasato YR, Halleen JM, Hentunen T, Yam LT. Serum tartrate-resistant acid phosphatase isoforms in rheumatoid arthritis. Clin Chim Acta. 2002; 320: 49-58.
17. Janckila AJ, Parthasarathy RN, Parthasarathy LK, Seelan RS, Hsueh YC, Rissanen J, Alatalo SL, Halleen JM, Yam LT. Properties and expression of human tartrate-resistant acid phosphatase isoform 5a by monocyte-derived cells. J Leuk Biol. 2005; 77: 209-218.
18. Janckila AJ, Slone SP, Lear SC, Martin A, Yam LT. Tartrate-resistant acid phosphatase as an immunohistochemical marker for inflammatory macrophages. Am J Clin Pathol. 2007; 127: 556-566.
19. Janckila AJ, Neustadt DH, Yam LT. Significance of serum TRACP in rheumatoid arthritis. J Bone Miner Res. 2008; 23: 1287-1295.
20. Kalantar-Zadeh K, Kalantar-Zadeh K, Lee GH. The fascinating but deceptive ferritin: To measure it or not to measure it in chronic kidney disease? Clin J Am Soc Nephrol. 2006; 1: S9-S18.
21. Ketteler M. Fetuin-A and extraosseous calcification in uremia. Curr Opin Nephrol Hypertens. 2005; 14: 337-342.
22. Koizumi M, Takahashi S, Ogata E. Comparison of serum bone resorption markers in the diagnosis of skeletal metastasis. Anticancer Res. 2003; 23: 4095-4100.
23. Ljusberg J, Wang Y, Lang P, Norgard M, Dodds R, Hultenby K, Ek-Rylander B, Andersson G. Proteolytic excision of a repressive loop domain in tartrate-resistant acid phosphatase by cathepsin K in osteoclasts. J Biol Chem. 2005; 280: 28370-28381.
24. López Gavilanes E, Parra EG, de la Piedra C, Caramelo C, Rapado A. Clinical usefulness of serum carboxyterminal propeptide of procollagen I and tartrate-resistant acid phosphatase determinations to evaluate bone turnover in patients with chronic renal failure. Miner Electrolyte Metab. 1994; 20: 259-264.
25. Lowrie EG. Acute-phase inflammatory process contributes to malnutrition, anemia, and possibly other abnormalities in dialysis patients. Am J Kidney Dis. 1998; 32: S105-S112.
26. Malyszko J, Malyszko JS, Pawlak K, Wolczynski S, Mysliwec M. Tartrate-resistant acid phosphatase 5b and its correlations with other markers of bone metabolism in kidney transplant recipients and dialyzed patients. Adv Med Sci. 2006; 51: 69-72.
27. Nakasato YR, Janckila AJ, Halleen JM, Väänänen HK, Walton SP, Yam LT. Clinical significance of immunoassays for Type 5 tartrate-resistant acid phosphatase. Clin Chem. 1999; 45: 2150-2157.
28. Nenonen A, Cheng S, Ivaska KK, Alatalo SL, Lehtimäki T, Schmidt-Gayk H, Uusi-Rasi K, Heionen A, Kannus P, Sievänen H, Vuori I, Väänänen HK, Halleen JM. Serum TRACP5b is a usefulmarker for monitoring alendronate treatment: comparison with other markers of bone turnover. J Bone Miner Res. 2005; 20: 1804-1812.
29. Räisänen SR, Alatalo SL, Ylipahkala H, Halleen JM, Cassady AI, Hume DA, Väänänen HK. Macrophages overexpressing tartrate-resistant acid phosphatase show altered profile of free radical production and enhanced capacity of bacterial killing. Biochem Biophys Res Commun. 2005; 331: 120-126.
30. Rissanen JP, Suominen MI, Peng Z, Halleen JM. Secreted tartrate-resistant acid phosphatase 5b is a marker of osteoclast number in human osteoclast cultures and the rat ovariectomy model. Calcif Tissue Int. 2008; 82: 105-115.
31. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raji L, Spinosa DJ, Wilson PW. Kidney disease as a risk factor for development of cardiovascular disease. Circulation. 2003; 108: 2154-2169.
32. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D, CHOIR Investigators. Correction of anemia with epoeitin-α in chronic kidney disease. N Engl J Med. 2006; 355: 2085-2098.
33. Stenvinkel P, Heimbürger O, Paultre F, Diczfalusy U, Wang T, Berglund L, Jogestrand T. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int. 1999; 55: 1899-1911.
34. Stepán JJ, Lachmanová J, Straková M, Pacovsky V. Serum osteocalcin, bone alkaline phosphatase isoenzymes and plasma tartrate resistant acid phosphatase in patients on chronic maintenance hemodialysis. Bone Miner Res. 1987; 3: 177-183.
35. Sträter N, Jasper B, Scholte M, Krebs B, Duff AP, Langley DB, Han R, Averill BA, Freeman HC, Guss JM. Crystal structures of recombinant human purple acid phosphatase with and without an inhibitory conformation of the repression loop. J Mol Biol. 2005; 351: 233-246.
36. Takahashi K, Janckila AJ, Sun SZ, Lederer ED, Ray PC, Yam LT. Electrophoretic study of tartrate-resistant acid phosphatase isoforms in end stage renal disease and rheumatoid arthritis. Clin Chim Acta. 2000; 301: 147-158.
37. Tsai S-H, Chen C-Y, Ku C-H, Janckila AJ, Yam LT, Yu J-C, Chuang K-W, Chao T-Y. The semiquantitative bone scintigraphy index correlates with serum tartrate-resistant acid phosphatase activity in breast cancer patients with bone metastasis. Mayo Clin Proc. 2007; 82: 917-926.
38. Voorzanger-Rousselot N, Juillet F, Mareau E, Zimmermann J, Kalebic T, Garnero P. Association of 12 serum biochemical markers of angiogenesis, tumor invasion and bone turnover with bone metastasis from breast cancer: a crossectional and longitudinal evaluation. Br J Cancer. 2006; 95: 506-514.
39. Walsh NC, Cahill M, Carninci P, Kawai J, Okazaki Y, Hayashizaki Y, Hume DA, Cassady AI. Multiple tissue-specific promoters control expression of the murine tartrate-resistant acid phosphatase gene. Gene. 2003; 307: 111-123.
40. Yilmaz MI et al. Low-grade inflammation in chronic kidney disease patients before the start of renal replacement therapy: sources and consequences. Clin Nephrol. 2007; 68: 1-9.
41. Zenger S, Hollberg K, Ljusberg J, Norgard M, Ek-Rylander B, Kiviranta R, Andersson G. Proteolytic processing and polarized secretion of tartrate-resistant acid phosphatase is altered in a subpopulation of metaphyseal osteoclasts in cathepsin K-deficient mice. Bone. 2007; 41: 820-832.
42. Zimmet P, Magliano D, Matsuzawa Y, Alberti G, Shaw J. The metabolic syndrome: A global public health problem and a new definition. J Atheroscler Thromb. 2005; 12: 295-300.